首页> 外文期刊>Current pharmaceutical design >Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus
【24h】

Differential influences of gastric bypass and sleeve gastrectomy on plasma nesfatin-1 and obestatin levels in patients with type 2 diabetes mellitus

机译:胃搭桥和袖胃切除术对2型糖尿病患者血浆nesfatin-1和obestatin水平的差异影响

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: The mechanisms by which bariatric surgeries, including gastric bypass (GB) and sleeve gastrectomy (SG), achieve remission of type 2 diabetes mellitus (T2DM) and sustained weight reduction are unknown. We hypothesized that the novel anorexic hormone nesfatin-1 and another new hormone obestatin might contribute to the marked improvement in glycemic homeostasis and weight loss in diabetics after GB and SG. Methods: A hospital-based, prospective study was conducted. Overnight fasting plasma concentrations of nesfatin-1 and obestatin were analyzed in T2DM patients before surgery, and at 3 and 12 months after laparoscopic GB (n =12) and SG (n = 6). Results: At 12 months, reductions of body mass index (BMI), fasting blood glucose, and glycated hemoglobin were similar between GB and SG groups (P all > 0.05). Plasma nesfatin-1 levels in patients undergoing GB or SG significantly decreased after surgeries (P both < 0.05). In contrast, plasma obestatin concentrations significantly increased in patients after SG (P < 0.05) but without any alteration after GB. The alterations of plasma nesfatin-1 were significantly and negatively associated with the reduction of fasting blood glucose (P < 0.05) at 12 months after GB and SG. In the SG group, the reduction of nesfatin-1 significantly and positively correlated with the decrease of BMI (P < 0.05). Conclusions: GB and SG produce differential influences with regards to circulating nesfatin-1 and obestatin levels in non-morbidly obese, T2DM patients. Circulating nesfatin-1 may modulate glucose homeostasis in two surgical procedures, and participate in regulating body weight in SG.
机译:目的:减肥手术(包括胃旁路手术(GB)和袖胃切除术(SG))实现2型糖尿病(T2DM)缓解和持续减轻体重的机制尚不清楚。我们假设新型厌食激素nesfatin-1和另一种新型激素oestatin可能有助于GB和SG后糖尿病患者血糖稳态和体重减轻的显着改善。方法:进行了一项基于医院的前瞻性研究。在T2DM患者术前,腹腔镜手术后3个月和12个月时,GB(n = 12)和SG(n = 6)对Nsfatin-1和Obestatin的空腹血浆浓度进行了分析。结果:在12个月时,GB组和SG组的体重指数(BMI),空腹血糖和糖化血红蛋白的降低相似(P均> 0.05)。手术后接受GB或SG的患者血浆nesfatin-1水平显着降低(P均<0.05)。相比之下,SG后患者的血浆雌激素浓度显着增加(P <0.05),但GB后无任何改变。 GB和SG后12个月血浆nesfatin-1的变化与空腹血糖的降低呈显着负相关(P <0.05)。在SG组,nesfatin-1的减少与BMI的减少呈显着正相关(P <0.05)。结论:GB和SG对非病态肥胖T2DM患者的循环nesfatin-1和obestatin水平产生不同的影响。循环nesfatin-1可通过两种外科手术调节葡萄糖稳态,并参与SG的体重调节。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号